Epidemiological Patterns and Risk Determinants of Neurodegenerative Diseases in the Context of Global Population Aging
DOI:
https://doi.org/10.61173/65wdya32Keywords:
Neurodegenerative diseases, Population aging, Epidemiology, Risk factorsAbstract
With the acceleration of global population ageing, neurodegenerative diseases (NDDs) have emerged as a major challenge threatening the health of the elderly and societal development. This paper reviews the epidemiological characteristics and risk factors of major NDDs such as Alzheimer’s disease and Parkinson’s disease, focusing on their variations across different regions, age groups, genders, socioeconomic statuses, and the combined effects from lifestyle, psychosocial and environmental factors. Research indicates that the prevalence of NDDs increases significantly with age. Women are more susceptible to Alzheimer’s disease, while men face a higher risk of Parkinson’s disease. Individuals from lower socioeconomic backgrounds experience markedly elevated incidence rates due to constrained access to healthcare and poorer living conditions. NDDs not only cause cognitive and motor impairments but also impose substantial economic and social burdens. We have also explored the basic mechanisms of different risk factors that increase the risk of NDDs, including physical exercise, alcohol consumption, sleep disturbances, depression and stress, social engagement and overall environmental factors. Understanding the epidemiological patterns and risk factors facilitates the development of targeted public health policies and interventions to mitigate the future disease burden. This study not only provides data support for epidemiological research but also offers reference for global health governance and the optimisation of healthcare resource allocation.
References
[1] Gianfredi, V., Nucci, D., Pennisi, F. et al. Aging, longevity, and healthy aging: the public health approach. Aging Clin Exp Res 37, 125 (2025). https://doi.org/10.1007/s40520-025-03021-8
[2] WHO. Aging and health. World Health Organization. (2024) https://www.who.int/news-room/fact-sheets/detail/ageing-andhealth
[3] WHO, Health topics: ageing. World Health Organization. https://www.who.int/health-topics/ageing#tab=
[4] Batista, P. S. P. (2016). Quality of life in patients with neurodegenerative diseases. Journal of Neurology and Neuroscience, 7(1), Article 74. https://doi.org/10.21767/2171- 6625.100074
[5] Jiang, Q., Liu, J., Huang, S. et al. Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances.Sig Transduct Target Ther 10, 76 (2025).https://doi. org/10.1038/s41392-025-02145-7
[6] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures, (2024) pp.3708–3821.https://doi.org/10.1002/ alz.13809.
[7] WHO.Dementia.World Health Organization. (2025)https:// www.who.int/news-room/fact-sheets/detail/dementia
[8] Wang S, Jiang Y, Yang A, Meng F, Zhang J. The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need. Aging Dis. 2024 Nov 4;16(5):2937-2952. doi: 10.14336/AD.2024.1071. PMID: 39571158; PMCID: PMC12339136.
[9] Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga- Ontoso I (2017). Prevalence and incidence of Alzheimer’s disease in Europe: A meta-analysis. Neurologia, 32:523-532.
[10] Uwishema, Olivier MDa; Kassahun Bekele, Bezawit MDa,h,c; Nazir, Abubakar MBBSa,d,*; Filbert Luta, Erick MDa,e,f; Abdulnaser Al-Saab, Elaf MDa,g; Jacques Desire, Irakiza MDa,b; Franklin Ozioma, Chukwuma MDa,i; Wojtara, Magda MDa. Breaking barriers: addressing inequities in Alzheimer’s disease diagnosis and treatment in Africa. Annals of Medicine & Surgery 86(9):p 5299-5303, September 2024. | DOI: 10.1097/MS9.0000000000002344
[11] Michael G. Erkkinen, Mee-Ohk Kim and Michael D. Geschwind. Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPublished in Advance July 17, 2017, doi:10.1101/cshperspect. a033118.
[12] Prof Andrew J Lees, MD ∙ Prof John Hardy, PhD ∙ Prof Tamas Revesz, FRCPath.Parkinson’s disease. The Lancet, Volume 373, Issue 9680, 2055 - 2066, June 13, 2009
[13] Bianco A, Antonacci Y, Liguori M. Sex and Gender Differences in Neurodegenerative Diseases: Challenges for Therapeutic Opportunities. International Journal of Molecular Sciences. 2023; 24(7):6354. https://doi.org/10.3390/ ijms24076354
[14] Glenda E. Gillies, Ilse S. Pienaar, Shiv Vohra, Zahi Qamhawi. Sex differences in Parkinson’s disease.Volume 35, Issue 3, August 2014, Pages 370-384. https://doi.org/10.1016/ j.yfrne.2014.02.002
[15] Charlotte A Haaxma, Bastiaan R Bloem, George F Borm, Wim J G Oyen, Klaus L Leenders, Silvia Eshuis, Jan Booij, Dean E Dluzen, Martin W I M Horstink. Gender differences in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry 2007; 78 787-787 Published Online First: 16 Jul 2007. doi: 10.1136/jnnp.2006.109991
[16] Danielle S. Abraham a b, Ann L. Gruber-Baldini a, Laurence S. Magder a, Patrick F. McArdle, Sarah E. Tom, Erik Barr, Katrina Schrader, Lisa M. Shulman. Sex differences in Parkinson’s disease presentation and progression. Parkinsonism & Related Disorders.Volume 69, December 2019, Pages 48-54. https://doi.org/10.1016/j.parkreldis.2019.10.01
[17] Almeida-Meza P, Steptoe A, Cadar D. Markers of cognitive reserve and dementia incidence in the English Longitudinal Study of Ageing. The British Journal of Psychiatry. 2021;218(5):243-251. doi:10.1192/bjp.2020.54
[18] Wang AY, Hu HY, Ou YN, Wang ZT, Ma YH, Tan L, Yu JT. Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 39 Prospective Studies. J Prev Alzheimers Dis. 2023;10(1):83-94. doi: 10.14283/jpad.2022.81. PMID: 36641612.
[19] Roberts AL, Johnson NJ, Chen JT, Cudkowicz ME, Weisskopf MG. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology. 2016 Nov 29;87(22):2300-2308. doi: 10.1212/WNL.0000000000003298. Epub 2016 Oct 14. PMID: 27742817; PMCID: PMC5135021.
[20] Mahalakshmi B, Maurya N, Lee SD, Bharath Kumar V. Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration. Int J Mol Sci. 2020 Aug 16;21(16):5895. doi: 10.3390/ijms21165895. PMID: 32824367; PMCID: PMC7460620.
[21] Peng B, Yang Q, B Joshi R, Liu Y, Akbar M, Song BJ, Zhou S, Wang X. Role of Alcohol Drinking in Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020 Mar 27;21(7):2316. doi: 10.3390/ijms21072316. PMID: 32230811; PMCID: PMC7177420.
[22] Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. Dean&Francis ISSN 2959-409X The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention. J Prev Alzheimers Dis. 2021;8(3):313- 321. doi: 10.14283/jpad.2021.15. PMID: 34101789; PMCID: PMC12280729.
[23] Justice NJ. The relationship between stress and Alzheimer’s disease. Neurobiol Stress. 2018 Apr 21; 8:127-133. doi: 10.1016/ j.ynstr.2018.04.002. PMID: 29888308; PMCID: PMC5991350.
[24] Influence of social network on occurrence of dementia: a community-based longitudinal study Fratiglioni, Laura et al. The Lancet, Volume 355, Issue 9212, 1315 - 1319
[25] Biddle KD, d’Oleire Uquillas F, Jacobs HIL, Zide B, Kirn DR, Rentz DM, Johnson KA, Sperling RA, Donovan NJ. Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults. Am J Geriatr Psychiatry. 2019 Nov;27(11):1247-1256. doi: 10.1016/j.jagp.2019.05.005. Epub 2019 May 10. PMID: 31248770; PMCID: PMC6778491.
[26] Olloquequi J, Díaz-Peña R, Verdaguer E, Ettcheto M, Auladell C, Camins A. From Inhalation to Neurodegeneration: Air Pollution as a Modifiable Risk Factor for Alzheimer’s Disease. Int J Mol Sci. 2024 Jun 25;25(13):6928. doi: 10.3390/ ijms25136928. PMID: 39000036; PMCID: PMC11241587.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
